Advances in Clinical Management of Stage Endometrial Cancer

Tian-yu ZHANG,Yi-qin WANG,Jian-liu WANG
DOI: https://doi.org/10.3969/j.issn.1674-1870.2017.04.006
2017-01-01
Abstract:The incidence of stageⅡendometrial cancer accounts for about 12%of endometrial cancer. The combination of the dilationand curettage, hysteroscopy and the imaging technique is a good choice for diagnosis. At present, the surgical approach of stage Ⅱ endometrial cancer is controversial, different studies have come to different conclusions, to expand the resection range to reduce the recurrence rate also increased intraoperative and postoperative complications. We should carefully balance the benefits of prognosis and increasing risk of surgery in selecting the surgical range. More prospective experiments are needed. Postoperative radiotherapy can reduce the recurrence rate, but have no effect on the overall survival rate. And vaginal brachytherapy may be better than pelvic radiotherapy. Adjuvant chemotherapy is needed in high-risk stage Ⅱ endometrial cancer. The three year survival rate of stageⅡendometrial cancer is 79%-85%. The diagnosis, treatment and prognosis of stageⅡendometrial cancer, which is the endometrial cancer patients with cervical stromal involvement [new International Federation of Gynecology and Obstetrics (FIGO) stageⅡ] are reviewed.
What problem does this paper attempt to address?